| CAS NO: | 59-92-7 |
| 包装 | 价格(元) |
| 10mM (in 1mL Water) | 电议 |
| 200mg | 电议 |
| 1g | 电议 |
| Cas No. | 59-92-7 |
| 别名 | 左旋多巴; Levodopa; 3,4-Dihydroxyphenylalanine |
| 化学名 | (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid |
| Canonical SMILES | C1=CC(=C(C=C1CC(C(=O)O)N)O)O |
| 分子式 | C9H11NO4 |
| 分子量 | 197.19 |
| 溶解度 | ≥ 6.57mg/mL in Water with gentle warming |
| 储存条件 | Store at RT, stored under nitrogen,unstable in solution, ready to use. |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | L-DOPA is a natural form of DOPA used in the treatment of Parkinson's disease. L-DOPA is the precursor of dopamine and product of tyrosine hydroxylase.Target: Dopamine ReceptorL-DOPA (L-3,4-dihydroxyphenylalanine) is a chemical that is made and used as part of the normal biology of humans, some animals and plants. Some animals and humans make it via biosynthesis from the amino acid L-tyrosine. L-DOPA is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine collectively known as catecholamines. L-DOPA can be manufactured and in its pure form is sold as apsychoactive drug with the INN levodopa; trade names include Sinemet, Parcopa, Atamet, Stalevo, Madopar, Prolopa, etc. As a drug it is used in the clinical treatment of Parkinson's disease and dopamine-responsive dystonia.L-DOPA crosses the protective blood-brain barrier, whereas dopamine itself cannot. Thus, L-DOPA is used to increase dopamine concentrations in the treatment of Parkinson's disease and dopamine-responsive dystonia. This treatment was made practical and proven clinically by George Cotzias and his coworkers, for which they won the 1969 Lasker Prize. In addition, L-DOPA, co-administered with a peripheral DDCI, has been investigated as a potential treatment for restless leg syndrome. However, studieshave demonstrated "no clear picture of reduced symptoms". References: |
m.cnreagent.com